Zolex Therapeutics
Treatment for Drug-resistant Bacterial Infections
Company Overview
Snapshot
Founded in August 2016, Zolex Therapeutics operates with 1–10 employees. The company has raised $500,000 across one funding round. Zolex Therapeutics focuses on developing new classes of orally active, small-molecular-weight antibiotics targeting Staphylococcus aureus, including methicillin-resistant strains.
Business overview
Zolex Therapeutics is a drug company specializing in the development of novel antibiotics. The company's core technology focuses on creating orally active, small-molecular-weight antibiotics specifically designed to combat Staphylococcus aureus, including drug-resistant strains like MRSA. Operating within the Health Tech & Life Sciences sector, Zolex Therapeutics addresses critical needs in pharmaceuticals and biopharmaceutical drug discovery.
Log in to access full profile ›Company Intelligence Q&A
- What is Zolex Therapeutics' primary focus?
- Zolex Therapeutics is focused on the development of new classes of orally active, small-molecular-weight antibiotics that target Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus strains.
- When was Zolex Therapeutics founded?
- Zolex Therapeutics was founded in August 2016.
- What is the employee count for Zolex Therapeutics?
- Zolex Therapeutics has 1–10 employees.
- What is the total capital raised by Zolex Therapeutics?
- Zolex Therapeutics has raised a total of $500,000.
- What is the company's current product development stage?
- Zolex Therapeutics is currently in the R&D stage for its products, focusing on novel antibiotics. This stage involves research and development activities to bring new drug candidates to preclinical and clinical trials.